| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -990,947 | -2,061,193 | -8,352,012 | NaN |
| Stock-based compensation expense | 39,803 | -7,949 | -741,858 | 6,040,136 |
| Issuance of common stock for services | NaN | 0 | 840,000 | NaN |
| Prepaid expenses | 174,335 | -18,129 | -2,468 | 17,414 |
| Trade accounts payable and accrued liabilities | -257,153 | 207,394 | 74,419 | -332,580 |
| Due to related parties | 26,592 | 224,802 | NaN | NaN |
| Accrued compensation - officer | -417,470 | 417,470 | NaN | NaN |
| Net cash used in operating activities | -1,773,510 | -1,201,347 | -927,264 | -1,559,577 |
| Payments to related party | NaN | NaN | NaN | 0 |
| Payments under related party line of credit | NaN | NaN | NaN | 0 |
| Repayment to officer | -155,518 | 155,518 | NaN | NaN |
| Proceeds from sale of common stock, related party | NaN | 0 | 3,000,000 | 0 |
| Proceeds from issuance of insurance loan payable | 224,789 | NaN | NaN | NaN |
| Proceeds from sale of common stock | NaN | NaN | 4,502,239 | 1,047,769 |
| Net proceeds from sale of common stock | NaN | 6,553,209 | NaN | NaN |
| Repayments on insurance loan payable | 21,920 | NaN | NaN | NaN |
| Net cash provided by financing activities | 47,351 | 1,158,719 | 7,502,239 | 1,047,769 |
| Net change in cash | -1,726,159 | -42,628 | 6,574,975 | -511,808 |
| Cash, beginning of period | 7,286,670 | 7,329,298 | 1,266,131 | NaN |
| Cash, end of period | 5,560,511 | 7,286,670 | 7,329,298 | NaN |
Telomir Pharmaceuticals, Inc. (TELO)
Telomir Pharmaceuticals, Inc. (TELO)